Akoya Biosciences, a Marlborough firm analyzing tissues for therapy research, announced on Tuesday it had closed its initial public offering with gross proceeds reaching $151.3 million.
The IPO included 7,567,000 shares of its common stock, which were offered at the IPO pricing of $20 a share. The stock began trading on The Nasdaq Global Select Market on Friday, under the symbol AKYA.
The price currently sits at $22.80 a share. The company offers single-cell imaging solutions allowing researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response, according to the release.
J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Piper Sandler & Co., and Canaccord Genuity LLC acted as joint book-running managers for the offering.
